Faculty

Back to Index
Burton Eisenberg, MD
Professor of Clinical Surgery
Director, Hoag/Usc Cancer Program
Surgery
1 Hoag Dr. Health Sciences Campus Newport Beach

Publications

Upfront boost Gamma Knife "leading-edge" radiosurgery to FLAIR MRI-defined tumor migration pathways in 174 patients with glioblastoma multiforme: a 15-year assessment of a novel therapy. J Neurosurg. 2016 Dec; 125(Suppl 1):40-49. View in: PubMed

The role of margins in extremity soft tissue sarcoma. J Surg Oncol. 2016 Mar; 113(3):333-8. View in: PubMed

Recent advances in the management of liposarcoma. F1000Res. 2016; 5:2907. View in: PubMed

Contemporary Management of Retroperitoneal Soft Tissue Sarcomas. Curr Oncol Rep. 2015 Aug; 17(8):39. View in: PubMed

Contemporary Management of Retroperitoneal Soft Tissue Sarcomas. Curr Oncol Rep. 2015 Aug; 17(8):462. View in: PubMed

Significant Reduction of Late Toxicities in Patients With Extremity Sarcoma Treated With Image-Guided Radiation Therapy to a Reduced Target Volume: Results of Radiation Therapy Oncology Group RTOG-0630 Trial. J Clin Oncol. 2015 Jul 10; 33(20):2231-8. View in: PubMed

A proof of principle clinical trial to determine whether conjugated linoleic acid modulates the lipogenic pathway in human breast cancer tissue. Breast Cancer Res Treat. 2013 Feb; 138(1):175-83. View in: PubMed

The SSG XVIII/AIO trial: results change the current adjuvant treatment recommendations for gastrointestinal stromal tumors. Am J Clin Oncol. 2013 Feb; 36(1):89-90. View in: PubMed

Gastrointestinal stromal tumor--background, pathology, treatment. Hematol Oncol Clin North Am. 2012 Dec; 26(6):1239-59. View in: PubMed

Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132. Ann Surg Oncol. 2012 Apr; 19(4):1074-80. View in: PubMed

ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression. J Nucl Med. 2012 Apr; 53(4):567-74. View in: PubMed

Adjuvant and neoadjuvant imatinib therapy: current role in the management of gastrointestinal stromal tumors. Int J Cancer. 2011 Dec 1; 129(11):2533-42. View in: PubMed

Adjuvant and neoadjuvant imatinib therapy: current role in the management of gastrointestinal stromal tumors. Int J Cancer. 2011 Dec 01; 129(11):2533-42. View in: PubMed

Adjuvant and neoadjuvant therapy for primary GIST. Cancer Chemother Pharmacol. 2011 Jan; 67 Suppl 1:S3-8. View in: PubMed

Long-term results of a phase 2 study of neoadjuvant chemotherapy and radiotherapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. Cancer. 2010 Oct 1; 116(19):4613-21. View in: PubMed

Long-term results of a phase 2 study of neoadjuvant chemotherapy and radiotherapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. Cancer. 2010 Oct 01; 116(19):4613-21. View in: PubMed

High density DNA array analysis reveals distinct genomic profiles in a subset of gastrointestinal stromal tumors. Genes Chromosomes Cancer. 2009 Oct; 48(10):886-96. View in: PubMed

Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor. Mol Cancer Ther. 2009 Aug; 8(8):2172-82. View in: PubMed

Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol. 2009 Jan 01; 99(1):42-7. View in: PubMed

Conjugated linoleic acid (CLA) inhibits expression of the Spot 14 (THRSP) and fatty acid synthase genes and impairs the growth of human breast cancer and liposarcoma cells. Nutr Cancer. 2009; 61(1):114-22. View in: PubMed

Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol. 2009 Jan 1; 99(1):42-7. View in: PubMed

The insulin-like growth factor system as a potential therapeutic target in gastrointestinal stromal tumors. Cell Cycle. 2008 Oct; 7(19):2949-55. View in: PubMed

Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci U S A. 2008 Jun 17; 105(24):8387-92. View in: PubMed

The synthetic triterpenoid CDDO-Im inhibits fatty acid synthase expression and has antiproliferative and proapoptotic effects in human liposarcoma cells. Cancer Invest. 2008 Mar; 26(2):118-27. View in: PubMed

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008 Feb 1; 26(4):620-5. View in: PubMed

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008 Feb 01; 26(4):620-5. View in: PubMed

Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol. 2007 Jan 1; 25(1):146-62. View in: PubMed

Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol. 2007 Jan 01; 25(1):146-62. View in: PubMed

Combined-modality strategy for gastrointestinal stromal tumors. Semin Oncol. 2006 Dec; 33(6 Suppl 11):S75-8. View in: PubMed

Combining imatinib with surgery in gastrointestinal stromal tumors: rationale and ongoing trials. Clin Colorectal Cancer. 2006 Nov; 6 Suppl 1:S24-9. View in: PubMed

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol. 2006 Oct 10; 24(29):4764-74. View in: PubMed

Phase II trial of preoperative chemoradiation with a hyperfractionated radiation boost in locally advanced rectal cancer. Am J Clin Oncol. 2006 Oct; 29(5):435-41. View in: PubMed

Therapeutic effect of imatinib in gastrointestinal stromal tumors: AKT signaling dependent and independent mechanisms. Cancer Res. 2006 May 15; 66(10):5477-86. View in: PubMed

Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. J Clin Oncol. 2006 Feb 01; 24(4):619-25. View in: PubMed

Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. J Clin Oncol. 2006 Feb 1; 24(4):619-25. View in: PubMed

Management of gastrointestinal stromal tumors in the imatinib era: selected case studies. Oncologist. 2006 Jan; 11(1):9-20. View in: PubMed

Soft tissue sarcomas: opportunities for defining the molecular phenotype of a solid tumor malignancy. Curr Opin Oncol. 2005 Jul; 17(4):355-6. View in: PubMed

Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modeling. Clin Cancer Res. 2005 May 15; 11(10):3668-77. View in: PubMed

Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res. 2004 Sep 15; 64(18):6476-81. View in: PubMed

Soft tissue sarcomas treated with postoperative external beam radiotherapy with and without low-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys. 2004 Jun 01; 59(2):475-80. View in: PubMed

Soft tissue sarcomas treated with postoperative external beam radiotherapy with and without low-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys. 2004 Jun 1; 59(2):475-80. View in: PubMed

Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy. Ann Surg Oncol. 2004 May; 11(5):465-75. View in: PubMed

NCCN Task Force report: optimal management of patients with gastrointestinal stromal tumor (GIST)--expansion and update of NCCN clinical practice guidelines. J Natl Compr Canc Netw. 2004 May; 2 Suppl 1:S-1-26; quiz 27-30. View in: PubMed

Is reporting of recurrence data important in pancreatic cancer? Ann Surg Oncol. Is reporting of recurrence data important in pancreatic cancer? Ann Surg Oncol. 2004 Mar; 11(3):304-9. View in: PubMed

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003 Dec 1; 21(23):4342-9. View in: PubMed

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003 Dec 01; 21(23):4342-9. View in: PubMed

Imatinib mesylate: a molecularly targeted therapy for gastrointestinal stromal tumors. Oncology (Williston Park). 2003 Nov; 17(11):1615-20; discussion 1620, 1623, 1626 passim. View in: PubMed

Intraoperative radiotherapy in the multimodality approach to bone and soft tissue cancers. Surg Oncol Clin N Am. 2003 Oct; 12(4):1015-29. View in: PubMed

Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumors. Mol Cancer Ther. 2003 Aug; 2(8):699-709. View in: PubMed

Soft tissue sarcomas of adults: state of the translational science. Clin Cancer Res. 2003 Jun; 9(6):1941-56. View in: PubMed

Pharmacotherapy of gastrointestinal stromal tumours. Expert Opin Pharmacother. 2003 Jun; 4(6):869-74. View in: PubMed

Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: analysis of histopathology and outcome. Int J Gastrointest Cancer. 2003; 34(2-3):121-8. View in: PubMed

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002 Aug 15; 347(7):472-80. View in: PubMed

En bloc resection for locally advanced cancer of the pancreas: is it worthwhile? J Gastrointest Surg. 2002 Mar-Apr; 6(2):147-57; discussion 157-8. View in: PubMed

Powered bySC CTSI